These psychopharmacology thesis topics cover antidepressants, antipsychotics, mood stabilisers, anxiolytics, hypnotics, substance-use pharmacotherapy and the safety of psychiatric medicines for MD and DNB Pharmacology candidates. The psychopharmacology research topics support designs that can be completed within one thesis period using existing psychiatry services, prescribing records, validated assessment tools and routine investigations, provided recruitment and follow-up are available. Define the diagnosis, treatment exposure and primary outcome before preparing the psychopharmacology protocol and university-format psychopharmacology synopsis.
Last reviewed and updated: September 2026 · 2026–27 admissions
Antidepressants and depressive disorders
Drug utilisation pattern of antidepressants among adults with major depressive disorder attending a tertiary care psychiatry outpatient department, compared with National List of Essential Medicines recommendations: a cross-sectional prescription audit assessing prescribing indicators over twelve months.
Prescribing patterns of sertraline, escitalopram, fluoxetine and other antidepressants among newly diagnosed adults with major depressive disorder: a prospective observational study assessing treatment continuation and documented adverse drug reactions at three months.
Comparative utilisation of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors among adults treated for major depressive disorder: a cross-sectional study assessing prescribing frequency, acquisition cost and concordance with standard treatment guidelines.
Association between antidepressant polypharmacy and potential drug-drug interactions among adults receiving treatment for depressive disorders: a cross-sectional prescription study using a recognised interaction reference and documenting interaction severity at the index visit.
Adherence to antidepressant therapy among adults with major depressive disorder receiving sertraline, escitalopram or fluoxetine: a prospective observational study using the eight-item Morisky Medication Adherence Scale and assessing adherence at three months.
Association of antidepressant adherence with symptom status among adults receiving stable pharmacotherapy for major depressive disorder: a cross-sectional correlation study using the Patient Health Questionnaire Nine and eight-item Morisky Medication Adherence Scale.
Frequency and pattern of adverse drug reactions to antidepressants among adults attending a tertiary care psychiatry clinic: a prospective observational study using the World Health Organization Uppsala Monitoring Centre causality assessment system over six months.
Comparison of the Naranjo Adverse Drug Reaction Probability Scale with the World Health Organization Uppsala Monitoring Centre causality assessment system for antidepressant-related adverse drug reactions: a prospective observational agreement study among psychiatry outpatients.
Severity and preventability of antidepressant-associated adverse drug reactions among adults receiving routine psychiatric care: a prospective observational study using the Hartwig severity assessment scale and Schumock and Thornton preventability criteria.
Risk factors for selective serotonin reuptake inhibitor-associated sexual dysfunction among adults with major depressive disorder: a case-control study comparing affected and unaffected patients and assessing exposure to sertraline, escitalopram and fluoxetine.
Prevalence of antidepressant-associated sexual dysfunction among adults receiving selective serotonin reuptake inhibitors for at least eight weeks: a cross-sectional study using the Arizona Sexual Experience Scale and comparing individual generic medicines.
Association between antidepressant treatment and self-reported daytime somnolence among adults with major depressive disorder: a comparative cross-sectional study of mirtazapine versus selective serotonin reuptake inhibitors using the Epworth Sleepiness Scale.
Comparative frequency of weight gain among adults receiving mirtazapine, escitalopram or sertraline for depressive disorders: a retrospective record-based study assessing documented body-weight change during the first three months of treatment.
Incidence and characteristics of hyponatraemia among adults aged sixty years or older receiving selective serotonin reuptake inhibitors: a retrospective record-based study comparing sertraline, escitalopram and fluoxetine using routinely ordered serum sodium measurements within three months.
Potentially inappropriate antidepressant prescribing among psychiatric outpatients aged sixty-five years or older: a cross-sectional prescription audit using the American Geriatrics Society Beers Criteria and assessing prevalence at the index consultation.
Anticholinergic medication burden among older adults receiving antidepressant pharmacotherapy in a tertiary care psychiatry clinic: a cross-sectional study using the Anticholinergic Cognitive Burden Scale and assessing concurrent psychotropic polypharmacy at one visit.
Generic versus brand-name prescribing of antidepressants among adults with depressive disorders: a cross-sectional prescription audit comparing prescription practices with National Medical Commission guidance and calculating medicine cost per prescription during twelve months.
Cost variation among commonly prescribed brands of sertraline, escitalopram, fluoxetine, duloxetine and mirtazapine available in India: a cross-sectional pharmacoeconomic study using published drug price sources and calculating percentage cost variation.
Prescription completeness and legibility for antidepressant-containing prescriptions from a psychiatry outpatient department: a cross-sectional audit against World Health Organization good-prescribing principles assessing omission and documentation errors during six months.
Use of fixed dose psychotropic combinations containing antidepressants among adults attending psychiatry services: a cross-sectional prescription audit comparing formulations with the National List of Essential Medicines and assessing potentially irrational combinations.
Concordance of antidepressant prescribing with the National List of Essential Medicines among adults treated for depressive disorders: a retrospective prescription audit assessing essential-medicine prescribing proportion and average medicines per encounter over twelve months.
Knowledge, attitude and practice regarding antidepressant adverse drug reaction reporting among psychiatry residents and consultants: a cross-sectional questionnaire study using a validated pharmacovigilance instrument and assessing reporting experience during the preceding year.
Effect of a single structured pharmacovigilance teaching session on knowledge of antidepressant adverse drug reaction reporting among postgraduate residents: a before-and-after study using the same validated questionnaire immediately before and after teaching.
Completeness of adverse drug reaction reporting forms for antidepressant-related reactions submitted to a tertiary hospital monitoring centre: a retrospective record-based study comparing completed fields with Pharmacovigilance Programme of India reporting requirements over two years.
Factors associated with antidepressant treatment discontinuation among adults with major depressive disorder: a prospective observational study assessing adverse effects, medicine cost, treatment beliefs and adherence three months after routine prescription.
Relationship between patient knowledge of antidepressant therapy and medication adherence among adults with major depressive disorder: a cross-sectional correlation study using a validated medication knowledge questionnaire and the eight-item Morisky Medication Adherence Scale.
Self-medication with antidepressants and other psychotropic medicines among adult patients presenting to psychiatry outpatient services: a cross-sectional interview study assessing sources, medicines used, duration and adverse effects during the preceding six months.
Antidepressant prescribing in women of reproductive age attending psychiatry services: a cross-sectional audit comparing sertraline, escitalopram, fluoxetine and other agents with available pregnancy-safety recommendations and documenting contraceptive counselling at the index visit.
Psychotropic polypharmacy among adults receiving antidepressants for major depressive disorder with psychiatric comorbidity: a cross-sectional prescription study assessing number of psychotropics, potential interactions and guideline concordance at the index visit.
Concomitant use of benzodiazepines with antidepressants among adults newly treated for major depressive disorder: a retrospective prescription study assessing benzodiazepine selection, documented indication and continuation beyond twelve weeks.
Prescribing of proton pump inhibitors, analgesics and other non-psychiatric medicines with selective serotonin reuptake inhibitors: a cross-sectional study assessing potential clinically important drug interactions among adult psychiatry outpatients at the index visit.
Frequency of medication errors involving antidepressants in psychiatry inpatient discharge prescriptions: a retrospective record-based study comparing prescriptions with medication charts and assessing omission, duplication and dosing errors at discharge.
Comparative adverse drug reaction profiles of sertraline and escitalopram among adults with major depressive disorder: a prospective observational study using spontaneous patient reporting and structured questioning during routine follow-up within twelve weeks.
Association of antidepressant treatment beliefs with medication adherence among adults with major depressive disorder: a cross-sectional correlation study using the Beliefs about Medicines Questionnaire and eight-item Morisky Medication Adherence Scale at routine follow-up.
Prescribing of antidepressants for indications other than depressive disorders in a tertiary psychiatry clinic: a cross-sectional prescription audit assessing anxiety disorders, obsessive-compulsive disorder and pain-related indications and guideline concordance over twelve months.
Use of antidepressants among patients with chronic medical comorbidities attending psychiatry services: a cross-sectional study assessing medicine selection, potential drug interactions and dose adjustments in patients with diabetes, hypertension or cardiovascular disease.
Association between pill burden and adherence among adults receiving antidepressants with additional psychotropic medicines: a cross-sectional correlation study measuring daily medication count and eight-item Morisky Medication Adherence Scale scores at routine follow-up.
Patient awareness of common adverse effects and precautions for prescribed antidepressants in a teaching hospital psychiatry clinic: a cross-sectional interview study using a structured questionnaire and comparing awareness with information documented during the consultation.
Availability and stock-out patterns of antidepressants listed in the National List of Essential Medicines at a government teaching hospital pharmacy: a retrospective drug-store register study assessing monthly availability and prescription substitution over twelve months.
Agreement between patient-reported and case-record-documented antidepressant adverse effects among adults with major depressive disorder: a cross-sectional agreement study using a structured adverse-effect checklist and medical records from the same consultation.
Antipsychotics and schizophrenia spectrum disorders
Drug utilisation pattern of antipsychotic medicines among adults with schizophrenia attending a tertiary care psychiatry outpatient department: a cross-sectional prescription audit comparing prescribing indicators with National List of Essential Medicines recommendations over twelve months.
Comparative utilisation of first-generation and second-generation antipsychotic medicines among adults with schizophrenia: a cross-sectional prescription study assessing prescribing frequency, psychotropic polypharmacy and acquisition cost during the index consultation.
Antipsychotic polypharmacy among adults with schizophrenia receiving maintenance treatment: a cross-sectional prescription audit assessing prevalence, documented indications and concordance with standard treatment guidelines at a tertiary care teaching hospital.
Potential drug-drug interactions among adults receiving antipsychotic medicines for schizophrenia: a cross-sectional prescription study using a recognised interaction reference and assessing interaction frequency and severity at the index visit.
Frequency and pattern of adverse drug reactions to antipsychotic medicines among adults with schizophrenia: a prospective observational study using the World Health Organization Uppsala Monitoring Centre causality assessment system during six months.
Comparison of the Naranjo Adverse Drug Reaction Probability Scale with the World Health Organization Uppsala Monitoring Centre causality assessment system for antipsychotic-related adverse drug reactions: a prospective observational agreement study among psychiatry patients.
Severity and preventability of antipsychotic-associated adverse drug reactions among adults with schizophrenia: a prospective observational study using the Hartwig severity assessment scale and Schumock and Thornton preventability criteria during routine follow-up.
Prevalence of antipsychotic-induced extrapyramidal symptoms among adults with schizophrenia: a cross-sectional study using the Simpson-Angus Scale and comparing patients receiving haloperidol, risperidone and olanzapine at the index visit.
Prevalence of akathisia among adults receiving antipsychotic pharmacotherapy for schizophrenia: a cross-sectional comparative study using the Barnes Akathisia Rating Scale and comparing risperidone, olanzapine and haloperidol exposure.
Tardive dyskinesia among adults receiving long-term antipsychotic therapy for schizophrenia: a cross-sectional study using the Abnormal Involuntary Movement Scale and assessing associations with medicine type and treatment duration at enrolment.
Association of antipsychotic exposure with weight gain among adults with schizophrenia: a retrospective record-based comparative study evaluating olanzapine, risperidone and aripiprazole and documented body-weight change during the first three months.
Metabolic monitoring practices among adults receiving second-generation antipsychotic medicines for schizophrenia: a cross-sectional record audit assessing documentation of weight, blood pressure, glucose and lipid measurements against recommended monitoring schedules.
Comparative prevalence of metabolic abnormalities among adults receiving olanzapine versus risperidone for at least three months: a cross-sectional study using routinely ordered glucose, lipid, blood pressure and anthropometric measurements.
Frequency of hyperprolactinaemia-related symptoms among adults receiving risperidone, olanzapine or aripiprazole: a cross-sectional comparative study using a structured symptom questionnaire and routinely ordered prolactin measurements where available at the index visit.
Anticholinergic medicine co-prescribing among adults receiving antipsychotics for schizophrenia: a cross-sectional prescription audit assessing trihexyphenidyl use, duration and documented extrapyramidal symptoms at the index consultation.
Appropriateness of prophylactic trihexyphenidyl prescribing among adults receiving antipsychotic medicines for schizophrenia: a retrospective prescription audit comparing indications and treatment duration with standard treatment guideline recommendations over twelve months.
Adherence to antipsychotic pharmacotherapy among adults with schizophrenia attending outpatient care: a cross-sectional study using the Medication Adherence Rating Scale and assessing associations with dosing frequency, adverse effects and pill burden.
Association between antipsychotic adverse effects and medication adherence among adults with schizophrenia: a cross-sectional correlation study using the Glasgow Antipsychotic Side-effect Scale and Medication Adherence Rating Scale during routine follow-up.
Patient attitudes toward antipsychotic medicines and adherence among adults with schizophrenia: a cross-sectional correlation study using the Drug Attitude Inventory and Medication Adherence Rating Scale at a tertiary care psychiatry clinic.
Factors associated with treatment default among adults prescribed antipsychotic medicines for schizophrenia: a retrospective case-control study comparing patients with and without missed follow-up and assessing medicine-related factors during six months.
Generic versus brand-name prescribing of antipsychotic medicines among adults with schizophrenia: a cross-sectional audit comparing prescribing practices with National Medical Commission guidance and calculating medicine cost per prescription over twelve months.
Cost variation among commonly prescribed brands of risperidone, olanzapine, aripiprazole, quetiapine and amisulpride available in India: a cross-sectional pharmacoeconomic study using published drug price sources and percentage cost variation.
Concordance of antipsychotic prescribing with the National List of Essential Medicines among adults with schizophrenia: a retrospective prescription audit assessing essential-medicine use and average psychotropic medicines per encounter over twelve months.
Fixed dose psychotropic combination use among adults receiving treatment for schizophrenia: a cross-sectional prescription audit assessing formulation composition, clinical indication and inclusion of component medicines in the National List of Essential Medicines.
Prescription completeness and medication errors in antipsychotic-containing discharge prescriptions from psychiatry wards: a retrospective record-based study comparing discharge prescriptions with inpatient medication charts and assessing errors at discharge.
Use of long-acting injectable antipsychotic medicines among adults with schizophrenia in a teaching hospital: a retrospective prescription study assessing indications, previous oral antipsychotic exposure and documented follow-up during three months.
Comparative adherence among adults with schizophrenia receiving long-acting injectable versus oral antipsychotic medicines: a cross-sectional study using documented appointment adherence and Medication Adherence Rating Scale scores at three months.
Adverse drug reactions associated with long-acting injectable antipsychotic medicines among adults with schizophrenia: a prospective observational study assessing causality, severity and preventability during routine follow-up for three months.
Antipsychotic prescribing among adults aged sixty-five years or older attending psychiatry services: a cross-sectional audit using the American Geriatrics Society Beers Criteria and assessing potentially inappropriate medicine use at the index visit.
Anticholinergic burden among older adults receiving antipsychotic pharmacotherapy: a cross-sectional study using the Anticholinergic Cognitive Burden Scale and examining associations with psychotropic polypharmacy and documented falls during the preceding three months.
Antipsychotic use in women of reproductive age with schizophrenia: a cross-sectional prescription audit assessing medicine selection, pregnancy-safety considerations and documentation of reproductive counselling at the index consultation.
Knowledge, attitude and practice regarding metabolic monitoring during second-generation antipsychotic treatment among psychiatry prescribers: a cross-sectional questionnaire study using a validated instrument and comparing responses with recommended monitoring standards.
Effect of a single structured teaching session on knowledge of antipsychotic metabolic monitoring among postgraduate residents: a before-and-after study using a validated questionnaire administered immediately before and after teaching.
Completeness of adverse drug reaction reporting forms for antipsychotic-related reactions submitted to a tertiary hospital monitoring centre: a retrospective study comparing completed fields with Pharmacovigilance Programme of India requirements over two years.
Agreement between patient-reported antipsychotic adverse effects and adverse effects documented in clinical records among adults with schizophrenia: a cross-sectional agreement study using a structured adverse-effect checklist at the same visit.
Association between daily antipsychotic dosing frequency and medication adherence among adults with schizophrenia: a cross-sectional study comparing once-daily and multiple-daily regimens using the Medication Adherence Rating Scale during routine outpatient follow-up.
Prescribing of benzodiazepines alongside antipsychotic medicines among adults with schizophrenia: a retrospective prescription study assessing indications, medicine choice and continuation beyond twelve weeks against standard treatment recommendations.
Use of multiple psychotropic medicine classes among adults with schizophrenia and medical comorbidities: a cross-sectional study assessing antipsychotics, antidepressants, mood stabilizers and potential drug interactions at the index visit.
Availability and stock-out patterns of antipsychotic medicines included in the National List of Essential Medicines at a government hospital pharmacy: a retrospective register study assessing monthly availability and substitution over twelve months.
Association between antipsychotic pill burden and self-reported treatment satisfaction among adults with schizophrenia: a cross-sectional correlation study measuring daily tablet count and Treatment Satisfaction Questionnaire for Medication scores at routine follow-up.
Mood stabilizers and bipolar disorders
Drug utilisation pattern of mood stabilizing medicines among adults with bipolar disorder attending a tertiary care psychiatry clinic: a cross-sectional prescription audit comparing lithium carbonate, sodium valproate and other agents with standard treatment guidelines.
Comparative utilisation of lithium carbonate, sodium valproate and carbamazepine among adults with bipolar disorder: a retrospective prescription study assessing medicine selection, combination therapy and documented indications over twelve months.
Psychotropic polypharmacy among adults receiving mood stabilizing medicines for bipolar disorder: a cross-sectional prescription audit assessing concurrent antipsychotics, antidepressants and benzodiazepines and potential drug interactions at the index visit.
Adherence to mood stabilizing pharmacotherapy among adults with bipolar disorder: a cross-sectional study using the eight-item Morisky Medication Adherence Scale and assessing associations with dosing frequency, pill burden and adverse effects.
Association between patient beliefs about mood stabilizing medicines and adherence among adults with bipolar disorder: a cross-sectional correlation study using the Beliefs about Medicines Questionnaire and eight-item Morisky Medication Adherence Scale.
Frequency and pattern of adverse drug reactions to lithium carbonate among adults with bipolar disorder: a prospective observational study using the World Health Organization Uppsala Monitoring Centre causality assessment system during six months.
Frequency and pattern of adverse drug reactions to sodium valproate among adults with bipolar disorder: a prospective observational study assessing causality, severity and preventability during routine psychiatric follow-up over six months.
Comparison of the Naranjo Adverse Drug Reaction Probability Scale with the World Health Organization Uppsala Monitoring Centre causality assessment system for mood stabilizer-related adverse drug reactions: a prospective observational agreement study.
Severity and preventability of adverse drug reactions associated with mood stabilizing medicines among adults with bipolar disorder: a prospective study using the Hartwig severity assessment scale and Schumock and Thornton preventability criteria.
Association between lithium carbonate therapy and routinely documented thyroid abnormalities among adults with bipolar disorder: a retrospective record-based study assessing thyroid function measurements recorded within six months of treatment.
Association between lithium carbonate therapy and routinely documented renal function abnormalities among adults with bipolar disorder: a retrospective record-based study assessing serum creatinine measurements and documented dose modification within six months.
Monitoring practices for adults receiving lithium carbonate for bipolar disorder: a cross-sectional record audit comparing documentation of renal, thyroid and serum lithium assessments with standard monitoring recommendations during the preceding six months.
Monitoring practices for adults receiving sodium valproate for bipolar disorder: a cross-sectional record audit assessing liver function, blood counts, weight and reproductive counselling against standard treatment recommendations during six months.
Prescribing of sodium valproate among women of reproductive age with bipolar disorder: a cross-sectional prescription audit assessing documented pregnancy status, contraceptive counselling and alternative medicine consideration at the index visit.
Knowledge, attitude and practice regarding reproductive risks of sodium valproate among psychiatry prescribers: a cross-sectional questionnaire study using a structured validated instrument and assessing counselling practices during the preceding six months.
Effect of a single structured teaching session on knowledge of sodium valproate reproductive safety among postgraduate residents: a before-and-after questionnaire study assessing knowledge scores immediately before and after teaching.
Weight change among adults with bipolar disorder receiving sodium valproate versus lithium carbonate: a retrospective comparative study using routinely recorded body weight at treatment initiation and three months.
Self-reported tremor among adults receiving lithium carbonate, sodium valproate or other mood stabilizing medicines: a cross-sectional comparative study using a structured symptom assessment and evaluating medicine exposure at the index visit.
Hair loss associated with sodium valproate among adults with bipolar disorder: a cross-sectional study using structured adverse-effect questioning and comparing prevalence by treatment duration and prescribed daily dose at enrolment.
Gastrointestinal adverse effects among adults receiving lithium carbonate versus sodium valproate for bipolar disorder: a cross-sectional comparative study using structured symptom assessment and documenting current daily dose at the index visit.
Potential drug-drug interactions among adults receiving lithium carbonate with antihypertensive, analgesic or diuretic medicines: a cross-sectional prescription study using a recognised interaction reference and assessing interaction severity at one visit.
Potential drug-drug interactions among adults receiving carbamazepine with psychotropic and non-psychotropic medicines: a cross-sectional prescription study using a recognised interaction reference and categorising interaction severity at the index consultation.
Generic versus brand-name prescribing of mood stabilizing medicines among adults with bipolar disorder: a cross-sectional audit comparing prescribing practices with National Medical Commission guidance and calculating medicine cost per prescription.
Cost variation among commonly available brands of lithium carbonate, sodium valproate, divalproex sodium, carbamazepine and lamotrigine in India: a cross-sectional pharmacoeconomic study using published drug price sources.
Concordance of mood stabilizer prescribing with the National List of Essential Medicines among adults with bipolar disorder: a retrospective prescription audit assessing essential-medicine use and psychotropic medicines per encounter over twelve months.
Medication errors involving lithium carbonate, sodium valproate and carbamazepine in psychiatry discharge prescriptions: a retrospective record-based study comparing discharge orders with inpatient medication charts and assessing dosing, duplication and omission errors.
Completeness of counselling documentation for adults prescribed lithium carbonate: a retrospective record audit assessing advice regarding hydration, toxicity symptoms, interacting medicines and monitoring requirements at treatment initiation.
Patient knowledge of lithium carbonate precautions among adults with bipolar disorder: a cross-sectional interview study using a structured questionnaire and comparing knowledge with counselling documented in clinical records at the same visit.
Association between patient knowledge of lithium carbonate and medication adherence among adults with bipolar disorder: a cross-sectional correlation study using a structured knowledge questionnaire and eight-item Morisky Medication Adherence Scale.
Treatment discontinuation among adults prescribed lithium carbonate or sodium valproate for bipolar disorder: a retrospective comparative study assessing adverse effects, cost and follow-up default documented during the first six months.
Fixed dose psychotropic combination use among adults treated for bipolar disorder: a cross-sectional prescription audit assessing formulation components, clinical indication and concordance with the National List of Essential Medicines at the index visit.
Antipsychotic co-prescribing among adults receiving lithium carbonate or sodium valproate for bipolar disorder: a cross-sectional study assessing frequency, documented indication and potential interactions during maintenance treatment.
Antidepressant co-prescribing among adults receiving mood stabilizing medicines for bipolar disorder: a cross-sectional prescription audit assessing medicine choice, documented indication and concordance with standard treatment guidelines at the index visit.
Benzodiazepine co-prescribing among adults receiving mood stabilizing therapy for bipolar disorder: a retrospective prescription study assessing indication, duration and continuation beyond twelve weeks during routine psychiatric care.
Adverse drug reaction reporting practices for lithium carbonate and sodium valproate among psychiatry healthcare professionals: a cross-sectional knowledge, attitude and practice questionnaire study assessing reporting experience during the preceding year.
Completeness of adverse drug reaction reporting forms for mood stabilizer-related reactions submitted to a tertiary hospital monitoring centre: a retrospective study comparing documentation with Pharmacovigilance Programme of India requirements over two years.
Potentially inappropriate mood stabilizer and psychotropic co-prescribing among adults aged sixty-five years or older with bipolar disorder: a cross-sectional audit using the American Geriatrics Society Beers Criteria at the index consultation.
Anticholinergic burden among older adults with bipolar disorder receiving multiple psychotropic medicines: a cross-sectional study using the Anticholinergic Cognitive Burden Scale and assessing concurrent mood stabilizer exposure at routine follow-up.
Availability and stock-out patterns of lithium carbonate, sodium valproate and carbamazepine at a government teaching hospital pharmacy: a retrospective drug-store register study assessing monthly availability and prescription substitution over twelve months.
Association between total daily psychotropic pill burden and medication adherence among adults with bipolar disorder receiving maintenance pharmacotherapy: a cross-sectional correlation study using daily tablet counts and eight-item Morisky Medication Adherence Scale scores.
Anxiolytics, sedative-hypnotics and substance-use psychopharmacology
Drug utilisation pattern of benzodiazepines among adult psychiatry outpatients with anxiety and sleep disorders: a cross-sectional prescription audit assessing medicine selection, duration and concordance with standard treatment guidelines over twelve months.
Prescribing patterns of clonazepam, lorazepam, alprazolam and diazepam among adults attending psychiatry outpatient services: a cross-sectional study assessing indication, prescribed duration and concurrent psychotropic medicines at the index visit.
Long-term benzodiazepine prescribing among adult psychiatry outpatients: a retrospective prescription study assessing indications, continuous use beyond twelve weeks and documented review of continued need during six months.
Potentially inappropriate benzodiazepine prescribing among adults aged sixty-five years or older: a cross-sectional prescription audit using the American Geriatrics Society Beers Criteria and assessing concurrent central nervous system medicines at the index visit.
Association between benzodiazepine use and self-reported daytime somnolence among adult psychiatry outpatients: a comparative cross-sectional study using the Epworth Sleepiness Scale and comparing current users with non-users.
Association between benzodiazepine use and self-reported falls among adults aged sixty-five years or older attending psychiatry services: a cross-sectional study comparing current users and non-users and assessing falls during the preceding three months.
Adherence to prescribed benzodiazepine therapy among adults with anxiety disorders: a cross-sectional study using the eight-item Morisky Medication Adherence Scale and assessing associations with dosing frequency and treatment duration.
Patient knowledge regarding dependence, sedation and safe discontinuation of prescribed benzodiazepines: a cross-sectional interview study among adult psychiatry outpatients using a structured questionnaire at routine follow-up.
Frequency and pattern of adverse drug reactions associated with benzodiazepines among adult psychiatry patients: a prospective observational study using the World Health Organization Uppsala Monitoring Centre causality assessment system during six months.
Comparison of the Naranjo Adverse Drug Reaction Probability Scale with the World Health Organization Uppsala Monitoring Centre causality assessment system for benzodiazepine-related adverse drug reactions: a prospective observational agreement study.
Severity and preventability of benzodiazepine-associated adverse drug reactions among adult psychiatry patients: a prospective observational study using the Hartwig severity assessment scale and Schumock and Thornton preventability criteria.
Co-prescribing of benzodiazepines with antidepressants among adults with anxiety or depressive disorders: a cross-sectional prescription audit assessing medicine combinations, intended duration and continuation beyond twelve weeks.
Co-prescribing of benzodiazepines with antipsychotic medicines among adults with schizophrenia spectrum disorders: a retrospective prescription study assessing indications, treatment duration and potential drug interactions during six months.
Potential drug-drug interactions among adults prescribed benzodiazepines with other central nervous system depressants: a cross-sectional prescription study using a recognised interaction reference and categorising interaction severity at the index visit.
Generic versus brand-name prescribing of benzodiazepines among adult psychiatry outpatients: a cross-sectional audit comparing practice with National Medical Commission guidance and calculating medicine cost per prescription over twelve months.
Cost variation among commonly available Indian brands of clonazepam, lorazepam, alprazolam and diazepam: a cross-sectional pharmacoeconomic study using published drug price sources and calculating percentage cost variation.
Concordance of benzodiazepine prescribing with the National List of Essential Medicines among adult psychiatry patients: a retrospective prescription audit assessing essential-medicine use, indication and prescribed duration over twelve months.
Prescription completeness for benzodiazepine-containing prescriptions in a psychiatry outpatient department: a cross-sectional audit assessing dose, frequency, duration and prescriber documentation against World Health Organization good-prescribing principles.
Knowledge, attitude and practice regarding rational benzodiazepine prescribing among psychiatry residents and consultants: a cross-sectional questionnaire study using a validated instrument and assessing prescribing practices during the preceding six months.
Effect of a single structured teaching session on knowledge of rational benzodiazepine prescribing among postgraduate residents: a before-and-after study using the same validated questionnaire immediately before and after teaching.
Self-medication with sedative-hypnotic medicines among adults attending psychiatry outpatient services: a cross-sectional interview study assessing medicines obtained without current prescription, sources and self-reported adverse effects during six months.
Use of over-the-counter and prescription sleep medicines among adults presenting with insomnia symptoms: a cross-sectional interview study assessing medicine type, source, duration and self-reported daytime impairment at enrolment.
Psychotropic medicine utilisation among adults receiving treatment for alcohol use disorder in a teaching hospital: a cross-sectional prescription audit assessing benzodiazepines, anticraving medicines and vitamin supplementation during routine care.
Prescribing pattern of naltrexone, acamprosate and disulfiram among adults with alcohol use disorder: a retrospective record-based study assessing patient characteristics, medicine selection and documented continuation at three months.
Adherence to anticraving pharmacotherapy among adults with alcohol use disorder receiving naltrexone or acamprosate: a prospective observational study using the eight-item Morisky Medication Adherence Scale at three months.
Adverse drug reactions associated with naltrexone, acamprosate and disulfiram among adults treated for alcohol use disorder: a prospective observational study assessing causality, severity and preventability during three months.
Monitoring practices among adults prescribed disulfiram for alcohol use disorder: a retrospective record audit assessing documented counselling, liver function testing and contraindication screening against standard treatment recommendations at initiation.
Patient knowledge of disulfiram-alcohol reactions among adults prescribed disulfiram for alcohol use disorder: a cross-sectional interview study using a structured questionnaire and comparing responses with documented counselling at the same visit.
Prescribing of benzodiazepines during routine management of alcohol withdrawal in adult inpatients: a retrospective record-based drug utilisation study assessing medicine choice, dosing pattern and duration against institutional treatment guidelines.
Medication errors involving benzodiazepines during inpatient management of alcohol withdrawal: a retrospective record review comparing medication charts with discharge summaries and assessing dosing, duplication and omission errors during admission.
Psychotropic medicine utilisation among adults receiving treatment for opioid dependence at a tertiary care de-addiction service: a cross-sectional prescription audit assessing prescribed medicines, psychotropic polypharmacy and potential interactions at the index visit.
Adherence to buprenorphine-based maintenance therapy among adults with opioid dependence receiving routine de-addiction services: a prospective observational study assessing pharmacy attendance and self-reported adherence during three months.
Adverse drug reactions reported among adults receiving buprenorphine-based maintenance therapy for opioid dependence: a prospective observational study using the World Health Organization Uppsala Monitoring Centre causality assessment system during three months.
Potential drug-drug interactions among adults receiving buprenorphine with benzodiazepines, antidepressants or antipsychotic medicines: a cross-sectional prescription study using a recognised interaction reference and categorising interaction severity.
Patient knowledge regarding sedative interactions during buprenorphine treatment for opioid dependence: a cross-sectional interview study using a structured questionnaire and assessing concurrent self-reported benzodiazepine or alcohol exposure at enrolment.
Prescribing of nicotine replacement medicines and other pharmacotherapy among adults attending a tobacco cessation clinic: a cross-sectional drug utilisation study assessing medicine selection, counselling documentation and follow-up status at three months.
Adherence to nicotine replacement therapy among adults attending a tobacco cessation clinic: a prospective observational study using a structured adherence questionnaire and assessing treatment continuation at four weeks and three months.
Adverse effects of nicotine replacement therapy among adults attending a tobacco cessation clinic: a prospective observational study assessing causality, severity and treatment continuation during the first four weeks of routine therapy.
Availability and stock-out patterns of benzodiazepines and medicines used for substance-use disorders in a government teaching hospital pharmacy: a retrospective register study assessing monthly availability and prescription substitution over twelve months.
Association between sedative psychotropic pill burden and self-reported daytime functioning among adult psychiatry outpatients: a cross-sectional correlation study using daily sedative medicine count and the Epworth Sleepiness Scale at routine follow-up.
Psychopharmacology prescribing safety, adherence, pharmacovigilance and rational use
Overall psychotropic drug utilisation among adult psychiatry outpatients at a tertiary care teaching hospital: a cross-sectional prescription audit using World Health Organization prescribing indicators and the National List of Essential Medicines over twelve months.
Psychotropic prescribing patterns among adult psychiatry inpatients at discharge: a retrospective record-based study assessing medicine classes, polypharmacy, generic prescribing and concordance with the National List of Essential Medicines over twelve months.
Psychotropic polypharmacy among adult psychiatry outpatients with at least one chronic medical comorbidity: a cross-sectional prescription study assessing number of medicines, potential interactions and guideline concordance at the index visit.
Potential drug-drug interactions among adult psychiatry outpatients receiving two or more psychotropic medicines: a cross-sectional study using a recognised interaction reference and categorising interaction frequency and severity at the index visit.
Potentially inappropriate psychotropic medicine use among psychiatry patients aged sixty-five years or older: a cross-sectional prescription audit using the American Geriatrics Society Beers Criteria and assessing prevalence at the index consultation.
Anticholinergic medication burden among older adult psychiatry outpatients receiving multiple psychotropic medicines: a cross-sectional study using the Anticholinergic Cognitive Burden Scale and assessing association with documented falls during the preceding three months.
Psychotropic medication adherence among adults receiving treatment for chronic psychiatric disorders: a cross-sectional study using the eight-item Morisky Medication Adherence Scale and assessing associations with pill burden, dosing frequency and medicine cost.
Association between psychotropic adverse-effect burden and medication adherence among adult psychiatry outpatients: a cross-sectional correlation study using a structured adverse-effect checklist and the eight-item Morisky Medication Adherence Scale.
Association between treatment beliefs and adherence to psychotropic medicines among adults with chronic psychiatric disorders: a cross-sectional correlation study using the Beliefs about Medicines Questionnaire and eight-item Morisky Medication Adherence Scale.
Factors associated with psychotropic treatment default among adult psychiatry outpatients: a retrospective case-control study comparing patients with and without missed scheduled follow-up and assessing medicine-related factors during six months.
Frequency and pattern of adverse drug reactions to psychotropic medicines reported from psychiatry services: a prospective observational study using the World Health Organization Uppsala Monitoring Centre causality assessment system during twelve months.
Comparison of the Naranjo Adverse Drug Reaction Probability Scale with the World Health Organization Uppsala Monitoring Centre causality assessment system for psychotropic adverse drug reactions: a prospective observational agreement study.
Inter-observer agreement in causality assessment of psychotropic adverse drug reactions using the World Health Organization Uppsala Monitoring Centre causality assessment system: a prospective study comparing two independent trained assessors during twelve months.
Inter-observer agreement in severity assessment of psychotropic adverse drug reactions using the Hartwig severity assessment scale: a prospective observational study comparing two independent trained assessors among reported reactions during twelve months.
Inter-observer agreement in preventability assessment of psychotropic adverse drug reactions using Schumock and Thornton preventability criteria: a prospective observational study comparing two independent trained assessors during twelve months.
Severity and preventability profile of psychotropic adverse drug reactions reported from psychiatry services: a prospective observational study using the Hartwig severity assessment scale and Schumock and Thornton preventability criteria over twelve months.
Completeness of psychotropic adverse drug reaction reporting forms submitted to a tertiary hospital monitoring centre: a retrospective record-based study comparing completed fields with Pharmacovigilance Programme of India reporting requirements over two years.
Knowledge, attitude and practice regarding psychotropic adverse drug reaction reporting among doctors, nurses and pharmacists working in psychiatry services: a cross-sectional questionnaire study using a validated pharmacovigilance instrument.
Effect of a single structured pharmacovigilance teaching session on knowledge of psychotropic adverse drug reaction reporting among postgraduate residents: a before-and-after study using the same validated questionnaire immediately before and after teaching.
Barriers to adverse drug reaction reporting among prescribers working in psychiatry services: a cross-sectional questionnaire study using a validated instrument and assessing previous reporting behaviour during the preceding twelve months.
Generic prescribing of psychotropic medicines in a tertiary care psychiatry service: a cross-sectional prescription audit comparing observed prescribing with National Medical Commission guidance and the National List of Essential Medicines over twelve months.
Prescription completeness and legibility in a tertiary care psychiatry outpatient department: a cross-sectional audit against World Health Organization good-prescribing principles assessing patient, medicine, dose, duration and prescriber information over six months.
Medication errors in psychiatry inpatient discharge prescriptions: a retrospective record-based study comparing discharge prescriptions with final medication charts and assessing omission, duplication, dose, frequency and duration errors at discharge.
Fixed dose psychotropic combination prescribing in psychiatry outpatient practice: a cross-sectional prescription audit assessing formulation composition, documented indication and inclusion of component medicines in the National List of Essential Medicines.
Cost per prescription of psychotropic medicines among adult psychiatry outpatients: a cross-sectional pharmacoeconomic study comparing generic and commonly prescribed branded formulations using published Indian drug price sources during twelve months.
Cost variation among brands of frequently prescribed psychotropic medicines available in India: a cross-sectional pharmacoeconomic study using published drug price sources and calculating percentage price variation for equivalent strengths and formulations.
Availability of psychotropic medicines listed in the National List of Essential Medicines at a government teaching hospital pharmacy: a retrospective drug-store register study assessing monthly stock availability and stock-out duration over twelve months.
Association between government-pharmacy psychotropic medicine stock-outs and prescription substitution among psychiatry outpatients: a retrospective study linking monthly pharmacy availability records with anonymised prescriptions during the same twelve-month period.
Quality of psychotropic drug promotional literature distributed to prescribers in a teaching hospital: a cross-sectional content analysis comparing claims and referenced information with World Health Organization ethical criteria for medicinal drug promotion.
Completeness and readability of package inserts supplied with commonly prescribed psychotropic medicines in India: a cross-sectional content analysis comparing required safety information with applicable Indian regulatory recommendations at the time of collection.
Knowledge, attitude and practice regarding rational psychotropic prescribing among postgraduate medical residents: a cross-sectional questionnaire study using a validated instrument and assessing familiarity with the National List of Essential Medicines.
Effect of a single structured rational-prescribing teaching session on postgraduate residents' psychotropic prescribing knowledge: a before-and-after study using standardised clinical prescribing scenarios administered immediately before and after teaching.
Translation and validation of a medication adherence questionnaire for regional-language-speaking adults receiving psychotropic medicines: a cross-sectional methodological study comparing the translated version with the original validated instrument at one assessment.
Translation and validation of a pharmacovigilance knowledge, attitude and practice questionnaire for regional-language-speaking healthcare professionals in psychiatry services: a cross-sectional methodological study assessing reliability and construct validity at one administration.
Accuracy of a brief self-reported medication adherence screening tool for adults receiving psychotropic medicines: a cross-sectional diagnostic accuracy study using pharmacy refill records over the preceding three months as the reference standard.
Agreement between patient-reported psychotropic medication use and medicines documented in outpatient clinical records: a cross-sectional medication-reconciliation study assessing concordance for medicine name, dose and frequency at the same visit.
Self-medication with psychotropic medicines among adults attending psychiatry outpatient services: a cross-sectional interview study assessing medicines used without current prescription, sources, indications and self-reported adverse effects during the preceding six months.
Psychotropic prescribing among pregnant women attending psychiatry and obstetric services in a teaching hospital: a retrospective record-based study assessing medicine classes, documented indications and concordance with recognised pregnancy-safety recommendations during pregnancy.
Psychotropic prescribing among children and adolescents attending a tertiary care psychiatry clinic: a cross-sectional prescription audit assessing medicine classes, weight-based dosing documentation, polypharmacy and concordance with standard treatment recommendations over twelve months.
Association between total psychotropic pill burden and treatment satisfaction among adults receiving long-term psychiatric pharmacotherapy: a cross-sectional correlation study using daily medication count and the Treatment Satisfaction Questionnaire for Medication at routine follow-up.
Not the pharmacology subspeciality you need? Psychopharmacology is one section of our full pharmacology collection — the hub page lists every subspeciality, each with its own free topic list. Updated September 2026.
📌 Updated for 2026–2027 MD Pharmacology admissions: Psychopharmacology
The research guidance has been reviewed for adequate treatment exposure, reliable symptom measurement, psychiatric safety monitoring and feasible follow-up.
Many projects can use psychiatry clinics, prescription records, locally validated symptom scales, anthropometry and routine glucose, lipid, renal or thyroid investigations as appropriate to the medicine studied.
Genotyping, neuroimaging and therapeutic drug assays are not required for every topic; confirm assay access, sampling schedules, trained raters and instrument permissions before selecting specialised projects.
Publication potential lies in well-defined questions about tolerability, adherence, treatment persistence and prescribing quality, with adequate exposure documentation and outcomes meaningful to patients.
Generate a protocol from any topic above
Select Generate Protocol → beside any title in the list above and receive a submission-ready document built around that topic, containing all eighteen components:
Introduction / Synopsis
Research Question
Aim of the Study
Primary Objective
Secondary Objectives
Materials and Methods
Inclusion Criteria
Exclusion Criteria
Sample Size Calculation
Methodology
Statistical Analysis
Ethical Considerations
Review of Literature
References
Gantt Chart / Study Timeline
Patient Information Sheet
Consent Form
Data Collection Form
Already have your thesis title?
Generate the full psychopharmacology protocol directly — objectives, methodology, sample size, statistics, timeline, references and annexures.
Alongside psychopharmacology protocols and synopses, support is also available for departmental presentations, journal club presentations, ethics committee presentations, and posters and oral presentations for medical conferences — for postgraduate residents, board trainees and research scholars across India and the GCC. Prepared by a practising doctor with long experience in medical publishing and thesis supervision.
The topics above work as research questions anywhere — what changes is the document the institution expects, and who approves it before data collection begins. The Gulf equivalent of an Indian synopsis is the psychopharmacology research proposal submitted to an institutional review board, and it ordinarily carries three sections an Indian synopsis does not: a Gantt chart, a budget and resources section, and a Declaration of Helsinki statement.
Board and residency programmes — country by country
Saudi Arabia — SCFHS and the Saudi Board. Residency and fellowship training under the Saudi Commission for Health Specialties includes a research project with a set timeline, and the psychopharmacology research proposal is the document prepared at the outset and cleared by the institutional review board before recruitment starts.
United Arab Emirates — DHA, DOH Abu Dhabi and MOHAP. Residents training in Dubai, Abu Dhabi and the northern emirates prepare a psychopharmacology research protocol for their programme and submit it for institutional review board approval before any data are collected.
Qatar — DHP (formerly QCHP) and Hamad Medical Corporation. A psychopharmacology IRB proposal is reviewed before recruitment, with the ethics section written to the institution's own template rather than a generic one.
Bahrain — NHRA. Trainees turning psychopharmacology research topics into a project need the proposal cleared by their institutional research and ethics committee before fieldwork begins.
Oman — OMSB. Residency programmes under the Oman Medical Specialty Board include a research component, and the psychopharmacology research proposal is the document assessed at the start of it.
Kuwait — KIMS. A psychopharmacology study protocol goes to the institutional committee for approval before the project begins.
Arab Board programmes across the region. The Arab Board carries its own research requirement irrespective of the host country, and the psychopharmacology proposal follows the same structure throughout.
Postgraduate degrees — Malaysia, the Gulf and beyond
Malaysia — MMed, the National Medical Research Register and MREC. A psychopharmacology dissertation proposal for a Master of Medicine programme carried out in a Ministry of Health facility must be registered on the NMRR and approved by the Medical Research and Ethics Committee before the study begins, and the guidance asks for submission four to six months ahead of data collection. Every investigator on the study team registers on the NMRR as well, so the methodology, ethics and team sections are written in far more detail than an Indian synopsis requires.
PhD and Master's candidates elsewhere. University programmes generally require a full psychopharmacology research proposal of roughly 6,000 to 10,000 words, with an extended literature review, a theoretical framework and a detailed methodology chapter.
PhD and MMed proposals are written individually by a medical doctor and revised until the supervisor accepts them. They are not produced by the automated protocol generator.
🔥 Trending research areas in Psychopharmacology for 2026–27
Metabolic health during psychotropic treatment: prospective assessment of weight, waist circumference, glucose and lipids can identify monitoring gaps and treatment-emergent changes when baseline risk and previous exposure are recorded.
Long-acting treatment and medication persistence: studying missed doses, discontinuation and relapse can address implementation questions, provided injectable and oral treatment groups are compared with attention to why each treatment was selected.
Precision psychopharmacology: drug concentrations and actionable gene–drug associations offer focused research questions where assays are available; altered metabolism alone does not establish that testing improves clinical outcomes.
Digital adherence and symptom measurement: evaluating app-based follow-up or electronic medication records against clinical assessments can test usefulness while accounting for missing entries, digital access and patient privacy.
Protocol and synopsis guidance
What a Psychopharmacology protocol must contain
Define the illness and treatment exposure. Specify the diagnostic framework, current episode, baseline severity, illness duration and previous treatment. Record the medicine, formulation, dose, titration, duration, adherence and reasons for switching or discontinuation. Capture concomitant sedatives, anticholinergics, psychotherapy, substance use and relevant smoking changes. These factors can affect both symptoms and drug exposure.
Define response before recruitment. Select one primary outcome and a named assessment tool with a suitable language version. State the response or remission threshold, assessment time points, rater training and blinding where feasible. Record rescue medication and time since the last dose when sedation may influence assessment. Reduced agitation or improved sleep should not automatically be interpreted as remission of psychosis, mania or depression.
Specify safety and treatment changes. Define how metabolic effects, movement disorders, sexual dysfunction, activation and withdrawal symptoms will be assessed when relevant. Distinguish adverse events from suspected adverse reactions and record baseline symptoms that might otherwise be attributed to treatment. Provide a named escalation route for suicidality and serious toxicity. In observational studies, prescribing decisions remain with the treating psychiatrist.
Psychopharmacology synopsis versus Psychopharmacology protocol
The synopsis presents the question, rationale and proposed methods in the university format. The protocol gives the operational details needed to conduct the study. Some institutions use the terms interchangeably; both should specify the same diagnosis, exposure definition, comparator, primary outcome and follow-up period.
Psychopharmacology protocols need explicit rules for cross-tapering, augmentation, rescue benzodiazepines, treatment interruption and hospital admission during follow-up. Record whether the analysis follows initial treatment or actual exposure over time. Do not introduce a research washout into an observational design. Define how consent capacity will be assessed, how symptom ratings will remain consistent and what happens when deterioration or adverse effects prevent a planned assessment.
Sample size and statistical analysis
Use the primary outcome to calculate sample size. A symptom-score comparison needs a clinically meaningful difference and expected variability; a response proportion needs an expected event risk. An adherence survey needs a prevalence estimate and precision. Allow for attrition and treatment changes. A sample adequate for weight change will usually be inadequate for rare severe toxicity or suicide-related outcomes.
Account for baseline severity and repeated assessments. Use baseline-adjusted or longitudinal methods appropriate to the design. Repeated ratings from one patient are correlated, and multiple scales create multiple-testing problems. Prespecify confounders such as illness duration, prior non-response, co-medication and substance use in observational comparisons. Report effect estimates with confidence intervals and distinguish statistical differences from clinically meaningful benefit.
Handle discontinuation transparently. Patients may stop treatment because of poor response, adverse effects, cost or recovery, so missing follow-up is not necessarily random. Record reasons, prespecify missing-data methods and conduct justified sensitivity analyses. Avoid presenting improvement among completers as the outcome of everyone enrolled. A non-significant difference between medicines does not establish equivalence.
1. How do I choose a feasible Psychopharmacology thesis topic?
For 2026–2027 admissions, choose a common psychiatric diagnosis, an accessible patient group and one outcome measurable within the available follow-up. Confirm collaboration with psychiatry, likely recruitment, medicine availability, assessment-tool permissions and routine laboratory support. A focused study of treatment tolerance, adherence or symptom change is generally more manageable than combining several diagnoses and drug classes with different treatment durations.
2. Which study designs are suitable for an MD Pharmacology thesis in psychopharmacology?
Depending on university requirements, options include cross-sectional prescribing or adherence studies, retrospective record reviews, prospective observational cohorts, case-control studies, economic evaluations and appropriately approved interventional trials. A cross-sectional survey can describe symptoms and current treatment but cannot determine whether a medicine caused improvement. Before-and-after studies also need careful interpretation because illness fluctuates and concomitant care may change.
3. What should I agree with my guide before finalising the topic?
Agree on the diagnosis, episode type, severity range, medicine exposure, comparator and primary endpoint. Confirm the minimum treatment duration, adherence assessment, recruitment target and follow-up schedule. Decide how switching, augmentation, rescue medication and substance use will be recorded. Settle rater training, scale permissions, laboratory access, consent-capacity procedures, urgent safety escalation and statistical support.
4. How should I select symptom scales and adverse-effect instruments?
Use instruments appropriate to the diagnosis, age, language and outcome, and check training and permission requirements. A depression scale is not a substitute for a mania or psychosis assessment. Define response and remission separately using a justified published approach. Measure sedation, extrapyramidal symptoms or sexual adverse effects separately when they could alter the main score. Train assessors consistently and check agreement where more than one rater performs assessments.
5. How does a Psychopharmacology synopsis differ from a protocol?
The synopsis summarises the study for university review; the protocol sets out how it will be performed. Both must agree on diagnosis, exposure, comparator, outcomes and analysis. The protocol also needs practical rules for titration, missed doses, treatment switching, rescue therapy, safety monitoring, consent reassessment and missing follow-up. Follow the institution's terminology and submission format.
6. What ethics safeguards are needed for Psychopharmacology research?
Obtain Institutional Ethics Committee approval before recruitment or research access to identifiable records. Assess capacity to consent for the specific research decision; a psychiatric diagnosis alone does not establish incapacity. Support understanding, protect voluntariness and reassess capacity when clinically indicated. If capacity is lacking, follow the applicable legal and ethics-approved safeguards rather than assuming a relative's signature is sufficient. Obtain parental or legal guardian consent and age-appropriate assent from about seven years for children.
Seek an approved consent waiver for eligible retrospective work. Obtain separate consent for identifiable photographs, audio or video. Routine-care observational studies should add no radiation, contrast or research-only venepuncture. If additional blood sampling is essential, justify it and state numerical limits in mL per draw and cumulatively, with weight-based limits for children, for ethics approval. Protect psychiatric, substance-use and sexual-health information through restricted access and coded records.
Name the treating psychiatrist as the first contact for suicidality, marked deterioration, suspected mania or serious adverse effects. Specify immediate emergency escalation for unstable patients and suspected severe drug toxicity, and referral for newly detected metabolic or other clinically important abnormalities. Explain confidentiality limits for urgent safety concerns during consent. Research participation must not delay care or prompt unsupervised treatment withdrawal; investigator-assigned treatment needs its applicable approvals and registration.
7. Do two previous antipsychotic prescriptions establish treatment-resistant schizophrenia?
No. Two prescriptions do not show that two adequate treatment trials occurred. Use a named operational definition, such as the Treatment Response and Resistance in Psychosis consensus criteria, and specify required symptom severity, functional impairment, dose, duration and adherence evidence. Confirm persistent symptoms despite the required adequately delivered trials.
Review the diagnosis, substance use, treatment interruptions, interacting medicines and reasons for stopping each drug. Discontinuation because of intolerance is not the same as non-response after adequate exposure. Use records, dispensing information, collateral history and drug concentrations where appropriate and available to strengthen exposure assessment. If adequacy cannot be established, classify it as uncertain rather than labelling the patient treatment-resistant. Different disorders require their own definitions of treatment resistance.
8. Can these topics support PhD proposals and Gulf board research projects?
They can provide starting questions after adapting the scope to the qualification. An MD synopsis usually supports a bounded supervised dissertation; a PhD proposal needs a stronger original contribution and a coherent programme of investigation. Transfer to another setting requires attention to local diagnostic practice, prescribing, language validation, medicine availability and consent procedures.
For SCFHS and Saudi Board training, the Arab Board of Health Specializations, and DHP, DHA, DOH or MOHAP-linked programmes, check the specific specialty curriculum and institution. Where a mandatory board research project applies, confirm supervision, local ethics approval, format and completion criteria. Requirements are programme-specific and cannot be inferred solely from the name of a licensing authority.
9. When should I register my Psychopharmacology thesis or study?
Confirm feasibility and supervisor agreement early, then submit the topic and synopsis within the university or board deadline. Obtain ethics approval and any applicable institutional or regulatory permissions before starting research activities. Complete required prospective trial registration before enrolling the first participant; Indian studies should establish the applicable Clinical Trials Registry-India requirements with the ethics committee. Thesis registration, ethics approval and trial registration are separate steps.
Found a topic that fits your department?
Generate its full protocol — objectives, methodology, sample size, statistics, timeline, references and annexures — in editable format.
